Abstract
The concept of using viruses as oncolytic agents is not a new one. In an effort to improve the applicability of viral anti-cancer agents various non-human viruses are being evaluated preclinically and clinically. The application of replication- competent non-human viruses poses new potential hazards, i.e. those associated with the possible adaptation of the therapeutic viruses to the human hosts. Therefore it is essential to weigh the potential benefits for the patients against the risk for the patients, their close contacts, and the greater public. Many aspects of such assessment parallel with the risks and dilemmas associated with the use of live porcine cells, tissues and organs in a clinical xenotransplantation setting. In this review we will summarize the potential biological hazards and list the points that need to be considered in a formal biosafety risk evaluation. The risk evaluation should include the possible environmental aspects of the non-human viruses used, also in case the non-human viruses are not formally designated as genetically modified organisms.
Keywords: Biosafety, oncolytic virus, environmental risk, virology, clinical trial.
Current Gene Therapy
Title:Biosafety of Non-Human Therapeutic Viruses in Clinical Gene Therapy
Volume: 13 Issue: 6
Author(s): Rob C. Hoeben, Derrick Louz and Danijela Koppers-Lalic
Affiliation:
Keywords: Biosafety, oncolytic virus, environmental risk, virology, clinical trial.
Abstract: The concept of using viruses as oncolytic agents is not a new one. In an effort to improve the applicability of viral anti-cancer agents various non-human viruses are being evaluated preclinically and clinically. The application of replication- competent non-human viruses poses new potential hazards, i.e. those associated with the possible adaptation of the therapeutic viruses to the human hosts. Therefore it is essential to weigh the potential benefits for the patients against the risk for the patients, their close contacts, and the greater public. Many aspects of such assessment parallel with the risks and dilemmas associated with the use of live porcine cells, tissues and organs in a clinical xenotransplantation setting. In this review we will summarize the potential biological hazards and list the points that need to be considered in a formal biosafety risk evaluation. The risk evaluation should include the possible environmental aspects of the non-human viruses used, also in case the non-human viruses are not formally designated as genetically modified organisms.
Export Options
About this article
Cite this article as:
Hoeben C. Rob, Louz Derrick and Koppers-Lalic Danijela, Biosafety of Non-Human Therapeutic Viruses in Clinical Gene Therapy, Current Gene Therapy 2013; 13 (6) . https://dx.doi.org/10.2174/156652321306140103224907
DOI https://dx.doi.org/10.2174/156652321306140103224907 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nucleoside Analogs as Anti-HBV Agents
Current Topics in Medicinal Chemistry An Overview of Innovations in Analysis and Beneficial Health Effects of Wine Polyphenols
Mini-Reviews in Medicinal Chemistry Computer Aided Drug Design for Combating Diseases (Part-III)
Current Topics in Medicinal Chemistry 3D QSAR of Aminophenyl Benzamide Derivatives as Histone Deacetylase Inhibitors
Medicinal Chemistry New Frontiers in Hydrogenase Structure and Biosynthesis
Current Chemical Biology Subject index to volume 3
Current Molecular Medicine Omecamtiv Mecarbil: A Myosin Motor Activator Agent with Promising Clinical Performance and New in vitro Results
Current Medicinal Chemistry Recent Updates on Biological Activities of Oxadiazoles
Mini-Reviews in Medicinal Chemistry SAR Study on Reactivators of Ethyl-Paraoxon Inhibited Acetylcholinesterase
Letters in Drug Design & Discovery Intervertebral Disc Engineering through Exploiting Mesenchymal Stem Cells: Progress and Perspective
Current Stem Cell Research & Therapy Current Status and Perspectives in the Development of Camptothecins
Current Pharmaceutical Design A Challenge for Medicinal Chemistry by the 17β-hydroxysteroid Dehydrogenase Superfamily: An Integrated Biological Function and Inhibition Study
Current Topics in Medicinal Chemistry Human Multidrug Transporter ABCG2, a Target for Sensitizing Drug Resistance in Cancer Chemotherapy
Current Medicinal Chemistry Proteases as Anti-Cancer Targets - Molecular and Biological Basis for Development of Inhibitor-Like Drugs Against Cancer
Anti-Cancer Agents in Medicinal Chemistry Synthesis, In Vitro and In Silico NS5B Polymerase Inhibitory Activity of Benzimidazole Derivatives
Medicinal Chemistry A Comprehensive Review on the Medicinal Benefits of Honey with an Emphasis on Unani Medicine
Current Traditional Medicine Atypical Manifestations of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children: A Systematic Review
Current Pediatric Reviews Fetal Risks of Maternal Diabetes
Current Women`s Health Reviews The Hellp Syndrome: A Review
Current Women`s Health Reviews Withdrawal Notice: Emerging Novel Coronavirus is a Global Threat: Insight in the Biology of COVID-19 and its Hijacking Process of Hosts’ Cell
Current Pharmaceutical Design